CIRSE Emprint Microwave Ablation Registry
CIEMAR
1 other identifier
observational
500
12 countries
37
Brief Summary
Observation of the clinical use of the Emprint Microwave Ablation System for the ablation of Liver Metastases of Colorectal Adenocarcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2019
Longer than P75 for all trials
37 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2018
CompletedFirst Posted
Study publicly available on registry
December 14, 2018
CompletedStudy Start
First participant enrolled
September 4, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 3, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2026
CompletedFebruary 11, 2026
February 1, 2026
3.3 years
December 11, 2018
February 9, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Local Tumor Control
Local Tumor Control at 12 months on a per lesion basis
12 months
Secondary Outcomes (7)
Number of participants with acute and/or chronic adverse events according to the latest version of CTCAE
3 years
Overall survival
3 years
Overall disease-free-survival
3 years
Hepatic disease-free-survival
3 years
Time to untreatable progression by thermal ablation
3 years
- +2 more secondary outcomes
Interventions
Microwave Ablation of colorectal liver metastases
Eligibility Criteria
Patients with colorectal adenocarcinoma and liver-only or liver-dominant metastatic disease
You may qualify if:
- years or older
- Proven colorectal liver metastases either histologically proven or diagnosed by imaging in a patient with known colorectal cancer
- Treated with the Emprint or Emprint HP Microwave ablation system
- Patient referred to MWA by a multidisciplinary tumour board
- Signed informed consent form
- Intention to completely treat (ablation, resection, SBRT) all visible disease within 8 weeks
- Maximum number of 9 total liver lesions
- All liver lesions must be local treatment-naive
- Maximum diameter of the largest liver lesion treated with MWA must not exceed 3cm
- Maximum diameter of lesions treated surgically may exceed this limitation
- Maximum number of 5 lung nodules eligible to be treated
- Patients may receive simultaneous liver resection and microwave ablation
- Patients may have received previous systemic therapy
- Patients treated with a liver-first approach may be included if treatment of the primary tumour is planned
- If applicable: complete response of treated rectal tumour proven by imaging
You may not qualify if:
- Life expectancy less than 6 months (palliative treatment)
- Extrahepatic metastases with the exception of a maximum of 5 lung nodules
- Ongoing infection (viral/bacterial)
- Patients receiving simultaneous bowel surgery and microwave ablation
- Patients receiving simultaneous IRE, RFA, SBRT, Cryoablation, HIFU or other local treatment than resection
- Pregnancy
- Patients with liver metastases that cannot be completely and safely treated
- Active cancers other than CRC
- Non-resected primary colon cancer
- Advanced liver disease or evidence of liver insufficiency
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (38)
University Hospital Centre Sisters of Mercy
Zagreb, 10000, Croatia
Aarhus University Hospital
Aarhus, 8200, Denmark
University Hospital of Nimes
Nîmes, 30900, France
CHU de Reims
Reims, 51092, France
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, 67000, France
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
Vivantes Klinikum Neukölln
Berlin, 12351, Germany
DRK Kliniken Berlin Westend
Berlin, 14050, Germany
Städtisches Klinikum Braunschweig
Braunschweig, 38126, Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, 01307, Germany
Krankenhaus Nordwest
Frankfurt, 60488, Germany
Universitätsklinikum Frankfurt
Frankfurt, 60596, Germany
Medizinische Hochschule Hannover
Hanover, 30625, Germany
SLK Kliniken Heilbronn
Heilbronn, 74078, Germany
Krankenhaus Barmherzige Brüder München
Munich, 80639, Germany
Universitätsklinikum Regensburg
Regensburg, 93053, Germany
Tübingen University Hospital
Tübingen, 72076, Germany
Attikon University Athens
Athens, 12462, Greece
Fondazione Poliambulanza Brescia
Brescia, 25124, Italy
IRCCS San Giuseppe Multimedica
Milan, 20123, Italy
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
European Institute of Oncology
Milan, 20141, Italy
Ospedaliero Universitaria San Luigi Gonzaga di Orbassano
Orbassano, 10043, Italy
Ospedale Santissima Annunziata
Taranto, 74121, Italy
Città della Salute e della scienza Torino
Torino, 10126, Italy
Vilnius University Hospital Santaros Klinikos
Vilnius, 08406, Lithuania
Amsterdam University Medical Center
Amsterdam, 1105 AZ, Netherlands
Universitair Medisch Centrum Groningen
Groningen, 9713, Netherlands
Leids Universitair Medisch Centrum
Leiden, 2333, Netherlands
City General Hospital 8th September
Skopje, 1000, North Macedonia
Oslo University Hospital
Oslo, 0372, Norway
Centro Hospitalar Universitário de Lisboa Central
Lisbon, 1169-050, Portugal
IPO Porto
Porto, 4200-072, Portugal
Hospital Universitari de Bellvitge
Barcelona, 08907, Spain
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Cukurova University Medical School
Adana, 01790, Turkey (Türkiye)
Hacettepe University Hospital
Ankara, 06230, Turkey (Türkiye)
Related Publications (1)
Pereira PL, Bale R, Fretland AA, Goldberg SN, Helmberger T, Meijerink MR, Orsi F, Stattner S, Vogl T, Kafkoula A, de Jong N, Zeka B, de Baere T. Local Tumour Control Following Microwave Ablation: Protocol for the Prospective Observational CIEMAR Study. Cardiovasc Intervent Radiol. 2024 Jan;47(1):121-129. doi: 10.1007/s00270-023-03573-0. Epub 2023 Oct 26.
PMID: 37884801RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Phillippe L. Pereira, PhD
Radiology, Minimally Invasive Therapies and Nuclear Medicine at SLK Clinics Heilbronn GmbH, Germany
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2018
First Posted
December 14, 2018
Study Start
September 4, 2019
Primary Completion
January 3, 2023
Study Completion
January 31, 2026
Last Updated
February 11, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share